针对尼塞利亚淋病菌的疫苗价值概况
Yiming Lyu1, Annabelle Choong2, Eric P F Chow3
1University of Melbourne, Parkville, Victoria 3010, Australia.
Vaccine
|December 20, 2023
概括
抗微生物耐药性需要新的尼塞里亚淋病 (淋病) 治疗方法. 有前途的候选疫苗,包括针对内性脑膜炎Neisseria meningitidis B血清组的疫苗,显示出控制这一全球健康威胁的潜力.
科学领域:
- 公共卫生 公共卫生
- 疫苗学 疫苗学 疫苗学
- 传染性疾病 传染性疾病
背景情况:
- 尼塞利亚淋病 (淋病) 感染对全球健康构成重大挑战.
- 增加抗微生物药物耐药性,特别是对 ceftriaxone 的耐药性,威胁到目前的治疗疗效.
- 缺乏经许可的冠状病毒疫苗凸显了对新型预防策略的迫切需要.
研究的目的:
- 提供对管道中的冠状病毒疫苗潜在的公共卫生,经济和社会价值的整体评估.
- 为利益相关者提供有关当前数据的信息,并确定疫苗开发的研究缺口.
- 引导开发可访问,负担得起和公平分配的冠状病毒疫苗.
主要方法:
- 针对尼塞利亚淋病的疫苗价值概况 (VVP) 的开发.
- 从同行评审的文献和报告中收集和评估现有数据.
- 来自具有多元代表性的工作组的专家共识.
主要成果:
- 观察数据表明,与尼塞利亚脑膜炎B血清组B疫苗 (4CMenB) 对淋病的潜在交叉保护 (30-40%的有效性).
- 4CMenB对淋病的疗效的临床试验正在进行中.
- 一个新的冠状病毒特异性疫苗候选人的1/2期研究正在进行中.
结论:
- 管道中的冠状病毒疫苗有望控制尼塞利亚淋病感染.
- 公平的获取和负担能力是疫苗部署的关键考虑因素.
- 进一步的研究和开发对于解决剩余的知识差距和确保疫苗成功至关重要.
关键词:
淋病 Gonorrhoea 这是一种淋病.不孕症 不孕不育 不孕不育 不孕不育尼塞里亚淋病菌 (Neisseria gonorrhoeae) 是一种传染病.OMV 男人B 疫苗的使用情况性传播感染性传播感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性感染性疫苗 疫苗 疫苗 疫苗价值档案是一个价值档案.
相关概念视频
01:31Defense Against Bacterial Pathogens
1.4K
The human immune system is a complex network of cells, tissues, and organs that work together to defend the body against bacterial infections. It consists of various immune cells, each playing a specific role in the defense mechanism.
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
1.4K
01:22Development of Immunocompetence
310
The initiation of cell-mediated immunity can be observed as early as the third month of fetal growth, with active antibody-mediated immunity following approximately one month later.
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
The initial cells that migrate from the fetal thymus settle within the skin and epithelial tissues lining the mouth, digestive tract, and in females, the uterus and vagina. These cells, including skin-based dendritic cells, serve as antigen-presenting cells, playing a key role in T cell activation.
Subsequent T...
310
01:51Vaccinations
44.5K
Overview
44.5K